Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017.. Alisertib (MLN8237) purchased from Selleck.

    Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

  • Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

    Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
1.2 nM 396.5 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXhNE42KM7:TR?= MUe3NkBp MmSwSG1UVw>? NF3XXm9KSzVyPUCuNFQh|ryP NWrMVGJwOjZzM{[2PFQ>
LS174T MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PRXlAvPSEQvF2= MlHJO|IhcA>? MXPEUXNQ MYLJR|UxRTBwMEWg{txO NF7DfI0zPjF|Nk[4OC=>
T84 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPWbmQxNjVizszN MWC3NkBp M4XiU2ROW09? MVPJR|UxRTBwMEmg{txO MV[yOlE{PjZ6NB?=
LS180 MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXsc2IxNjVizszN NWnD[mtrPzJiaB?= NUPTdo1jTE2VTx?= Ml7jTWM2OD1zIN88US=> MlTXNlYyOzZ4OES=
SW948 NGT1TpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSwMlUh|ryP NFnWemU4OiCq MmW5SG1UVw>? MnzLTWM2OD1zIN88US=> NHHlbVAzPjF|Nk[4OC=>
HCT15 NYnrU4drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSyNE42KM7:TR?= MYK3NkBp MmXVSG1UVw>? NEPKVW5KSzVyPECuOEDPxE1? NHrnbZozPjF|Nk[4OC=>
DLD-1 NH3ifmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLaV2FbOC53IN88US=> NU[ycWpFPzJiaB?= MXPEUXNQ M1\ScWlEPTB:MD64JO69VQ>? NHTLSZAzPjF|Nk[4OC=>
MIP-101 NI\K[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqwMlUh|ryP M{TZRVczKGh? M4naNGROW09? M1m2UGlEPTB;MTFOwG0> NXH5eFZzOjZzM{[2PFQ>
SNU1544 M3rpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDnbYNnOC53IN88US=> NIDRdYI4OiCq M2L1dmROW09? MYLJR|UxRTFizszN MVmyOlE{PjZ6NB?=
OCI-Ly10 NVvLe291S3m2b4TvfIlkKEG|c3H5 MXq3NkBp NH7iTYlFVVOR NGLUWFlKSzVyPUCuNFU5KM7:TR?= NVXmPVBFOjV6N{izN|E>
SU-DHL2 NVnSdHA3S3m2b4TvfIlkKEG|c3H5 NUXtfphxPzJiaB?= MV3EUXNQ MlrnTWM2OD1yLkCxJO69VQ>? M2CzT|I2QDd6M{Ox
OCI-LY7 MonNR5l1d3SxeHnjJGF{e2G7 NWnnTWVqPzJiaB?= M1\YWmROW09? MkPhTWM2OD1yLkC4NUDPxE1? MXiyOVg4QDN|MR?=
SU-DHL6 M2HYOWN6fG:2b4jpZ{BCe3OjeR?= NVn3OGptPzJiaB?= NWTsTVMxTE2VTx?= NWrRRnp{UUN3ME2wMlQ5OiEQvF2= NY\xO4J7OjV6N{izN|E>
Jeko-1 MXzDfZRwfG:6aXOgRZN{[Xl? M4m4clczKGh? NWraW|hMTE2VTx?= MY\JR|UxRTBwMEK5JO69VQ>? MonSNlU5Pzh|M{G=
JVM-2 MULDfZRwfG:6aXOgRZN{[Xl? MX63NkBp MlW2SG1UVw>? MYTJR|UxRTBwMEGg{txO NHjCT28zPTh5OEOzNS=>
Rec-1 MWPDfZRwfG:6aXOgRZN{[Xl? MnXXO|IhcA>? NXG2TI9jTE2VTx?= MUfJR|UxRTBwMEi3JO69VQ>? MWeyOVg4QDN|MR?=
Z-138 MlXQR5l1d3SxeHnjJGF{e2G7 NXy1UYV3PzJiaB?= NFXlToVFVVOR NYjUW5RpUUN3ME2wMlAyOyEQvF2= MU[yOVg4QDN|MR?=
H9 MWPDfZRwfG:6aXOgRZN{[Xl? NET1TY04OiCq M1P1TWROW09? MYnJR|UxRTBwNjFOwG0> NUDn[4x7OjV6N{izN|E>
HH NHj5OWJEgXSxdH;4bYMhSXO|YYm= NYPve4FzPzJiaB?= M4DH[GROW09? M2\lXmlEPTB;MD63JO69VQ>? MmfQNlU5Pzh|M{G=
DND41 M3LCOWN6fG:2b4jpZ{BCe3OjeR?= Mn62O|IhcA>? MV;EUXNQ MoXTTWM2OD1yLkGg{txO NHPFPXkzPTh5OEOzNS=>
CCL119 NFvvUpJEgXSxdH;4bYMhSXO|YYm= NHS1R4M4OiCq MXrEUXNQ NUjTSnZIUUN3ME2wMlA3OiEQvF2= NEDydpYzPTh5OEOzNS=>
J.Cam 1.6 MorqR5l1d3SxeHnjJGF{e2G7 NHfn[Ys4OiCq M4XGeGROW09? MlH3TWM2OD1yLkGwOUDPxE1? MYKyOVg4QDN|MR?=
Sup-T1 NV\JOFN3S3m2b4TvfIlkKEG|c3H5 M{jGOVczKGh? NWDpc4VNTE2VTx?= MX\JR|UxRTJwMUSyJO69VQ>? NHTZdVgzPTh5OEOzNS=>
Tib 152 Mn\aR5l1d3SxeHnjJGF{e2G7 MlrSO|IhcA>? MXjEUXNQ M4\hcmlEPTB;MD64JO69VQ>? Mo\jNlU5Pzh|M{G=
MCF7 MkW5SpVv[3Srb36gRZN{[Xl? MVu1JO69VQ>? NWPvSZl2OjRiaB?= NX\qUlNXTE2VTx?= NUDyPWxwUW6mdXPld{BIOi:PIHHydoV{fA>? MVSyOVg{PDRyMR?=
MDA-MB-231 NW\vNo01TnWwY4Tpc44hSXO|YYm= MkO3OUDPxE1? M4nV[lI1KGh? NETOW41FVVOR MVfJcoR2[2W|IFezM20h[XK{ZYP0 MnTPNlU5OzR2MEG=
MCF7 NYn3VG5ZTnWwY4Tpc44hSXO|YYm= NIPtPHA2KM7:TR?= MoPaNlQhcA>? MXzEUXNQ MYPE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ NFTLNZEzPTh|NESwNS=>
MCF7 Mo\NSpVv[3Srb36gRZN{[Xl? MnHPOUDPxE1? Mm\PNlQhcA>? Mn3PSG1UVw>? MV\E[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNi=> M4rlT|I2QDN2NECx
MCF7 MmrySpVv[3Srb36gRZN{[Xl? M362O|Uh|ryP NVTUZXB[OjRiaB?= NUflbYo3TE2VTx?= NYD1[m5oTGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=> M4LITFI2QDN2NECx
MCF7 NFq4W4ZHfW6ldHnvckBCe3OjeR?= MnnxOUDPxE1? NH7OblYzPCCq MV7EUXNQ M{LVVWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwNlEhX2GoMT;DbZAy M3L0dFI2QDN2NECx
MCF7 M3zmO2Z2dmO2aX;uJGF{e2G7 MmfKOUDPxE1? NFrRb5IzPCCq MXPEUXNQ NWGwXYZiUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx NW\zclhpOjV6M{S0NFE>
MDA-MB-231 NULONXV7TnWwY4Tpc44hSXO|YYm= NIfy[HE2KM7:TR?= NVz0bFhROjRiaB?= NFTwNJlFVVOR M17sfmRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsyN0OGQ{K= MVeyOVg{PDRyMR?=
MDA-MB-231 M1Xwb2Z2dmO2aX;uJGF{e2G7 NYPBZ4Z1OSEQvF2= NVnzRWxVOjRiaB?= NYjYWGc4TE2VTx?= M1zrbWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz MWGyOVg{PDRyMR?=
MDA-MB-231 MlvwSpVv[3Srb36gRZN{[Xl? NHHJV3M2KM7:TR?= MXOyOEBp M{\GNGROW09? NYjTVXo4TGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJIN6[2yrbjDCNS=> MYiyOVg{PDRyMR?=
MDA-MB-231 MYjGeY5kfGmxbjDBd5NigQ>? MoHnOUDPxE1? M4f3Z|I1KGh? Ml3SSG1UVw>? NVi5d2N2UW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzOSCZYX[xM2NqeDF? NY\LZnFOOjV6M{S0NFE>
MDA-MB-231 MnrRSpVv[3Srb36gRZN{[Xl? NHnxS3M2KM7:TR?= MmHVNlQhcA>? MWrEUXNQ NFXlToNKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= MWOyOVg{PDRyMR?=
MDA-MB-231 M{P6UGZ2dmO2aX;uJGF{e2G7 M2DRRVUh|ryP NGDpSoQzPCCq M17QbGROW09? MkGzTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=> NWTHfmRqOjV6M{S0NFE>
MCF7 NITMfoxCeG:ydH;zbZMhSXO|YYm= NIP2Z4M2KM7:TR?= NYrVR2ZKOjRiaB?= Mn;iSG1UVw>? NUfnTm1zUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= NUfScpNNOjV6M{S0NFE>
MDA-MB-231 NGS0UGVCeG:ydH;zbZMhSXO|YYm= M{jkdFUh|ryP MV2yOEBp MXzEUXNQ M3PZWWlv\HWlZYOgZZBweHSxdHnjJIRm[XSq NVy5bG5uOjV6M{S0NFE>
MCF7 NFvUVndHfW6ldHnvckBCe3OjeR?= Mnf1NUDPxE1? M4\PR|czKGh? NWjXXpF1TE2VTx?= M1fZPGlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= NWDCSohrOjV6M{S0NFE>
MDA-MB-231 M4rke2Z2dmO2aX;uJGF{e2G7 M2XHWlEh|ryP NUHoNVA{PzJiaB?= MXPEUXNQ NV7TNZZ7UW6mdXPld{BifXSxcHjh[4lkKGSnYYTo NFLDZoQzPTh|NESwNS=>
U-2 OS NHW1PVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\COVAh|ryP NYHRb4NkOjRiaB?= NUP4OZZSTE2VTx?= MVvJR|UxRTF4Lk[g{txO MUeyOVc6OjhzMR?=
MG-63 NWX0XGk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHQUFY2OCEQvF2= NF\VSXUzPCCq M1;FRmROW09? MWfJR|UxRTlwNTFOwG0> MV6yOVc6OjhzMR?=
U-2 OS NFz6d2hCeG:ydH;zbZMhSXO|YYm= NHnW[nc2KM7:TR?= MXmyOEBp NWLE[GpvTE2VTx?= MVHJcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYTo M{L3eFI2Pzl{OEGx
MG-63 M1vCUmFxd3C2b4Ppd{BCe3OjeR?= M2DtbFUh|ryP MUWyOEBp NWHDOGxTTE2VTx?= MojuTY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> NUDCZWtpOjV5OUK4NVE>
U-2 OS MnO2SpVv[3Srb36gRZN{[Xl? NHm0TFE2KM7:TR?= NVjNfop2OjRiaB?= NVm0e|ZWTE2VTx?= MV\Qdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> NUL4Oo85OjV5OUK4NVE>
MG-63 MnLnSpVv[3Srb36gRZN{[Xl? MWO1JO69VQ>? M{XtXlI1KGh? NYXaW5YxTE2VTx?= M{jtXXBzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? NI\XW4czPTd7MkixNS=>
PANC-1 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK1NEDPxE1? NUjYU40yOjRiaB?= MXfEUXNQ MWLJR|UxRTdwMTFOwG0> MmSwNlU3OzJ{MkW=
BxPC-3 NHfiVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHaOVAh|ryP MYqyOEBp NH7ISIRFVVOR M17xdGlEPTB;Nj64JO69VQ>? Ml3kNlU3OzJ{MkW=
PANC-1 Mnn2SpVv[3Srb36gRZN{[Xl? NHHtN4Q2KM7:TR?= M{\3WlI1KGh? NHrlNlZFVVOR NHnoSIZKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V? Mn;PNlU3OzJ{MkW=
BxPC-3 Mmf2SpVv[3Srb36gRZN{[Xl? NGjDco42KM7:TR?= MUSyOEBp NYHQW5lqTE2VTx?= NGfTZnFKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V? MXSyOVY{OjJ{NR?=
PANC-1 M1vXPGZ2dmO2aX;uJGF{e2G7 MlHQOUDPxE1? MYWyOEBp NV7oUotXTE2VTx?= NYjUR3VnUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? Ml;rNlU3OzJ{MkW=
BxPC-3 NULldVh4TnWwY4Tpc44hSXO|YYm= MlrwOUDPxE1? NXv1XYt[OjRiaB?= MmXKSG1UVw>? NWTFVoJUUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? NYL0dJhEOjV4M{KyNlU>
SKOV3 NGDGXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fBUVExOCEQvF2= NVjF[ZJ5OjRiaB?= NUTueWdxTE2VTx?= MlHYTWM2OD1{MD60PEDPxE1? MkPkNlU3OjR5NUC=
OVCAR4 NGPyUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH0VWwyODBizszN M4XoelI1KGh? NVfKcGEyTE2VTx?= MYnJR|UxRTJ{LkGzJO69VQ>? NHLsPFMzPTZ{NEe1NC=>
SKOV3 NGSyVWNHfW6ldHnvckBCe3OjeR?= MoHwOUDPxE1? Mo\YO|IhcA>? NEe3UINFVVOR NVfxZ2pFUW6mdXPld{BIOi:PIHHydoV{fA>? MoDINlU3OjR5NUC=
OVCAR4 NYiwb5Z7TnWwY4Tpc44hSXO|YYm= MoXtOUDPxE1? M{jjcFczKGh? NVXyfHhXTE2VTx?= MoTtTY5lfWOnczDHNk9OKGG{cnXzeC=> MmjrNlU3OjR5NUC=
SKOV3 MYDBdI9xfG:|aYOgRZN{[Xl? NVLJcZlrPSEQvF2= MmH0NlQhcA>? MWXEUXNQ NUDON41SUW6mdXPld{BieG:ydH;zbZM> MVeyOVYzPDd3MB?=
OVCAR4 MoW4RZBweHSxc3nzJGF{e2G7 Mn73OUDPxE1? NFTHSmozPCCq MkDqSG1UVw>? MofSTY5lfWOnczDhdI9xfG:|aYO= NFPBdZAzPTZ{NEe1NC=>
AGS M{GzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke1NlUh|ryP M1[yWVI1KGh? Mny3SG1UVw>? MkW4TWM2OD1zOT6wPUDPxE1? MYSyOVYxQTl{Mx?=
NCI-N78 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnrSVVJOjVizszN NX3LT4RuOjRiaB?= NHvPWHpFVVOR NIHyR4RKSzVyPUK2MlM{KM7:TR?= NHj0dJAzPTZyOUmyNy=>
AGS MWfBdI9xfG:|aYOgRZN{[Xl? NHPRS2k2KM7:TR?= MoHBNlQhcA>? NFnvUXNFVVOR MY\JcoR2[2W|IHHwc5B1d3Orcx?= NGXwdpgzPTZyOUmyNy=>
NCI-N78 MVLBdI9xfG:|aYOgRZN{[Xl? M4\Vd|Uh|ryP M2D5VFI1KGh? NYjiVVVrTE2VTx?= MkTNTY5lfWOnczDhdI9xfG:|aYO= NH;WZWkzPTZyOUmyNy=>
AGS NUDUcWRXTnWwY4Tpc44hSXO|YYm= NHXCNnk2KM7:TR?= MW[yOEBp NXXtcnRjTE2VTx?= M2fZcGlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? NWH4UWJ6OjV4MEm5NlM>
NCI-N78 NY[1PIxbTnWwY4Tpc44hSXO|YYm= MnHuOUDPxE1? NEj5UXAzPCCq MUjEUXNQ M4PmVWlv\HWlZYOgeIhmKGG3dH;wbIFogQ>? M3;rV|I2PjB7OUKz
HSC-3 NVnyOI5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;yNUDPxE1? MX20PEBp MY\JR|UxRTBwNUSg{txO MYiyOVM3PjF2Mx?=
GB30 M1XTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3DcGoyKM7:TR?= NGD0Olc4KGR? NVvpelNITE2VTx?= MljyTWM2OD1yLkCxNUDPxE1? MoTrNlUyODZ2Mki=
GB9 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSyVFRKOSEQvF2= MoPKO{Bl M1LlWGROW09? M2PIcWlEPTB;MD6wNlQh|ryP MnnNNlUyODZ2Mki=
GB169 NUTFWVc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvUZoIyKM7:TR?= MlXFO{Bl M13QSGROW09? NYTsR5lRUUN3ME2wMlA{OiEQvF2= NH;ZXJgzPTFyNkSyPC=>
T24 Mn7tSpVv[3Srb36gRZN{[Xl? MXuxJO69VQ>? MoTJOFghcA>? M2G4TWROW09? NXHnZXZrUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> M4LTeVI{PDB|NkOz
RT4 NYXtU4F2TnWwY4Tpc44hSXO|YYm= NHmyPIcyKM7:TR?= M2jyd|Q5KGh? MnfHSG1UVw>? M1u4TGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MnLoNlM1ODN4M{O=
UM-UC-3 M1TIbGZ2dmO2aX;uJGF{e2G7 MUSxJO69VQ>? NUCzS2pPPDhiaB?= Ml3vSG1UVw>? MWTJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 M2fXdFI{PDB|NkOz
T24 MofxRZBweHSxc3nzJGF{e2G7 MUCzMlE3KM7:TR?= MV65OkBp M2XmN2ROW09? M{XXbmlEPTB;MD6wN|A3KM7:TR?= M3\RSVI{PDB|NkOz
RT4 NHjmSHRCeG:ydH;zbZMhSXO|YYm= NUDnW3c4Oy5zNjFOwG0> M{Djdlk3KGh? NX3Ge2ZOTE2VTx?= MoLqTWM2OD1yLkGxPVgh|ryP M4TiR|I{PDB|NkOz
UM-UC-3 M1O4e2Fxd3C2b4Ppd{BCe3OjeR?= NYLHSFJMOy5zNjFOwG0> MWe5OkBp MV3EUXNQ MWXJR|UxRTBwMES0PUDPxE1? NIm5clczOzRyM{[zNy=>
OVCAR-5 M2ThXmZ2dmO2aX;uJGF{e2G7 NVmxWI1DPTBibl2= NFy4SY5KdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= MYWyN|M{PDN{Nx?=
SKOV3ip2 MoS0SpVv[3Srb36gRZN{[Xl? NHrJTm02OCCwTR?= MlvETY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? NVj5SohoOjN|M{SzNlc>
S462 NUHZRZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSxNFAh|ryP M3rGW|czKGh? NWLIS4VVTE2VTx?= M13DfmF1fGWwdXH0[ZMh[2WubDDndo94fGh? MV:yN|MzQDFzNB?=
2884 NG\sVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\tNVAxKM7:TR?= NIXTc404OiCq M2X5ZWROW09? M3j6N2F1fGWwdXH0[ZMh[2WubDDndo94fGh? NHewdVkzOzN{OEGxOC=>
2885 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrzdFgyODBizszN MkSzO|IhcA>? M1nLcmROW09? NVHRNYhbSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= M2WzbFI{OzJ6MUG0
CRL-2396 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPWcFA1OTByIN88US=> MoGye4F1\XJ? MYrJR|UxRTBwMEmyJO69VQ>? NXnNXVdQOjNzNUO1NlQ>
TIB-48 M4XwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfmenkyODBizszN MmDNe4F1\XJ? NEXDWGpKSzVyPUCuNFg5KM7:TR?= MX[yN|E2OzV{NB?=
CRL-2396 NWHGcWlyS3m2b4TvfIlkKEG|c3H5 NWLvc4loOSEQvF2= M333VVQ5KGh? M1PsfZdifGW{ MXTJcoR2[2W|IHHwc5B1d3Orcx?= MX2yN|E2OzV{NB?=
TIB-48 NEH5cGhEgXSxdH;4bYMhSXO|YYm= NV;Wd5AyOSEQvF2= MmPBOFghcA>? MX\3ZZRmeg>? NGS0PHBKdmS3Y3XzJIFxd3C2b4Ppdy=> MVWyN|E2OzV{NB?=
AGS NVz4VmcyS3m2b4TvfIlkKEG|c3H5 MXKwMlUh|ryP NIH6bmQzPCCq M{PmdGROW09? NW\LN2JWTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= M3K4dlIzQTd{NkGx
FLO-1 NH;ueItEgXSxdH;4bYMhSXO|YYm= M1HK[FAvPSEQvF2= NYPYOlNqOjRiaB?= M{jaNmROW09? NIHJNJFF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= M{\QUVIzQTd{NkGx
OE33 NGLyZVdEgXSxdH;4bYMhSXO|YYm= MlHSNE42KM7:TR?= NE[zWWQzPCCq NYPFV|l3TE2VTx?= M{OweGRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu M1TpTFIzQTd{NkGx
SKLMS NYrvcXY6S3m2b4TvfIlkKEG|c3H5 M2LO[Vc2KG6P M4HM[lk3KGh? NYDpNJFuUW6mdXPld{BieG:ydH;zbZM> NGrIOG4zOjh{MUm5Oy=>
Leio285 M4Xn[2N6fG:2b4jpZ{BCe3OjeR?= NYTyXnZJPzVibl2= NVvxbm5rQTZiaB?= NVTVUlN6UW6mdXPld{BieG:ydH;zbZM> M4T5fFIzQDJzOUm3
Mes-Sa M1fye2N6fG:2b4jpZ{BCe3OjeR?= NVqwUW9{PzVibl2= NWPqPGx3QTZiaB?= MYjJcoR2[2W|IHHwc5B1d3Orcx?= NFS2WokzOjh{MUm5Oy=>
DAOY NEDzPHdEgXSxdH;4bYMhSXO|YYm= NHLDbWUyOCEQvF2= NWrLXW9FPzJiaB?= M3e0fmROW09? MYHJR|UxRTBwMESg{txO M{L0RlIzPjZ7M{O1
IMR32 NEH1Sm5EgXSxdH;4bYMhSXO|YYm= NF3TfHAyOCEQvF2= M136eFczKGh? NF3ac5pFVVOR M3mwWWlEPTB;MD6wN{DPxE1? MYCyNlY3QTN|NR?=
Molt-4 NYr3WldSS3m2b4TvfIlkKEG|c3H5 MlLXNVAh|ryP MXy3NkBp NGG0VlVFVVOR NV;pToxRUUN3ME2wMlAzKM7:TR?= MUmyNlY3QTN|NR?=
MOLM-13 M1T4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPOdYZtOyEQvF2= NHP6Zpc4OiCq NUnLXZM{TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> Ml[0NlI1QDh{NEm=
HL-60 NXm1ZXVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqzJO69VQ>? M3;adFczKGh? NGPIfItFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MmrTNlI1QDh{NEm=
MV4-11 NXfBXXdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrj[3o{KM7:TR?= MnjVO|IhcA>? Ml7FSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NIm3UGQzOjR6OEK0PS=>
SKM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjXN{DPxE1? NYCxenhPPzJiaB?= MWXEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NGWxXJozOjR6OEK0PS=>
SH2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fy[lMh|ryP NF\sVWI4OiCq Mk[3SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= M{T6ZVIzPDh6MkS5
NOMO-1 NF;3W4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfuT2Q{KM7:TR?= NUW1dIVIPzJiaB?= NGTPWXBFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NIe2TXczOjR6OEK0PS=>
OCL-AML2 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPIN{DPxE1? MmWyO|IhcA>? MX3EbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NGr2W3gzOjR6OEK0PS=>
PL-21 NIHVcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHZN{DPxE1? NVfzPJp1PzJiaB?= MXnEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NXnzbXoxOjJ2OEiyOFk>
KG-1 M4LDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i3XlMh|ryP M{DQUVczKGh? MWnEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M2exOlIzPDh6MkS5
A172 NGLIXGFEgXSxdH;4bYMhSXO|YYm= Ml73NVAxKM7:TR?= NXTXUJNDOjRiaB?= M4fNfmROW09? M1n4WGlEPTB;MD6xNlAh|ryP M3vtZVIzOjd2M{m5
U87 M1zwO2N6fG:2b4jpZ{BCe3OjeR?= NWfjN49POTByIN88US=> NVuyemZqOjRiaB?= NUW0PGwyTE2VTx?= MofyTWM2OD1yLkGwOUDPxE1? NFWweZEzOjJ5NEO5PS=>
U251 MWDDfZRwfG:6aXOgRZN{[Xl? MYexNFAh|ryP M1zxRVI1KGh? MX;EUXNQ MmDiTWM2OD1yLkGwNEDPxE1? MkXpNlIzPzR|OUm=
T98 NWHYO2xvS3m2b4TvfIlkKEG|c3H5 M2TDR|ExOCEQvF2= MYOyOEBp MV\EUXNQ MUnJR|UxRTBwMUK1JO69VQ>? Mle3NlIzPzR|OUm=
LN18 MUHDfZRwfG:6aXOgRZN{[Xl? NFf4O4wyODBizszN M2TLUlI1KGh? MkPVSG1UVw>? NV3PUGZTUUN3ME2wMlIyOCEQvF2= M3fKPVIzOjd2M{m5
LN443 NUHOXGwyS3m2b4TvfIlkKEG|c3H5 MVKxNFAh|ryP NW\tWVR7OjRiaB?= M17Z[GROW09? NVmzUoE3UUN3ME2wMlIzOCEQvF2= NHjWbFEzOjJ5NEO5PS=>
HF66 NWfUZWY1S3m2b4TvfIlkKEG|c3H5 NF31[XcyODBizszN MVKyOEBp NXW0fnJOTE2VTx?= NYG3fpRpUUN3ME2wMlIzPSEQvF2= NF\zSlMzOjJ5NEO5PS=>
HF2303 MlSxR5l1d3SxeHnjJGF{e2G7 MWGxNFAh|ryP M{TMd|I1KGh? NYjtdngzTE2VTx?= NX3TTYNMUUN3ME2wMlA3OCEQvF2= NWL5UnFTOjJ{N{SzPVk>
HF2359 M2XrS2N6fG:2b4jpZ{BCe3OjeR?= NI\4[3EyODBizszN MYCyOEBp M2fHNGROW09? MmD6TWM2OD1yLkC2NEDPxE1? NWnEXoo5OjJ{N{SzPVk>
HF2414 NX;Pe4JqS3m2b4TvfIlkKEG|c3H5 M4P3TlExOCEQvF2= NF34UYIzPCCq MkPoSG1UVw>? Ml\sTWM2OD1yLkC4NEDPxE1? MX6yNlI4PDN7OR?=
A-673 NV7IfGVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHvbXNIOTBizszN MljzPVYhcA>? MoLCSG1UVw>? NVThVXZqUUN3ME2wMlA{OiEQvF2= M2\kRlIyPDR6NUmx
TC-32 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWmxNEDPxE1? NYiwdW9vQTZiaB?= M3\UOmROW09? MVLJR|UxRTBwMEO5JO69VQ>? MkDRNlE1PDh3OUG=
TC-71 NGrpc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexNEDPxE1? Mnv2PVYhcA>? MonzSG1UVw>? MWDJR|UxRTBwMUCyJO69VQ>? Mlv5NlE1PDh3OUG=
SK-N-MC NF2zWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSxNEDPxE1? NH\KT3M6PiCq NF7jPIJFVVOR MXHJR|UxRTBwMEeyJO69VQ>? M4GzVlIyPDR6NUmx
CHLA-9 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqxNEDPxE1? NGXITWs6PiCq MlPPSG1UVw>? NGO3WZZKSzVyPUCuNFE5KM7:TR?= M123b|IyPDR6NUmx
CHLA-10 NYHYPJo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO3c2IyOCEQvF2= NFvicHI6PiCq NIjJNplFVVOR NHHSWZpKSzVyPUCuNFYxKM7:TR?= MkLONlE1PDh3OUG=
CHLA-25 NXi3NZhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojVNVAh|ryP NX;UeXhZQTZiaB?= Ml7ESG1UVw>? NWLFVZVUUUN3ME2wMlE3QCEQvF2= NYC4TGliOjF2NEi1PVE>
CHLA-32 M3XtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO3NVAh|ryP MkX6PVYhcA>? NUjYZ|B[TE2VTx?= NHnFU|JKSzVyPUCuNVM3KM7:TR?= MVSyNVQ1QDV7MR?=
CHLA-56 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\lRlMyOCEQvF2= MVe5OkBp NYHNfpA6TE2VTx?= NIjuU|NKSzVyPUGwJO69VQ>? MlLPNlE1PDh3OUG=
CHLA-258 NF7QW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HNcVExKM7:TR?= NGDTcYE6PiCq NW[xRmZ5TE2VTx?= NVLS[o93UUN3ME2wMlE{OiEQvF2= NX7XWYFFOjF2NEi1PVE>
COG-E-352 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HtdVExKM7:TR?= MXW5OkBp MVnEUXNQ MmDCTWM2OD1yLkC0N{DPxE1? M2HNNlIyPDR6NUmx
CHLA-90 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDkem5POTBizszN NIm0PY06PiCq M1zmWmROW09? MmrDTWM2OD1yLkC2NUDPxE1? NXOwcGVROjF2NEi1PVE>
CHLA-119 MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P0dlExKM7:TR?= MXK5OkBp NHTDRmpFVVOR M3\wNGlEPTB;MD6wNlIh|ryP MoLWNlE1PDh3OUG=
CHLA-122 NYPIZZFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDl[npOOTBizszN M3K5PFk3KGh? MojKSG1UVw>? NXjofJRnUUN3ME2wMlAyQSEQvF2= NGHZS2gzOTR2OEW5NS=>
CHLA-136 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XZWVExKM7:TR?= MU[5OkBp NFnSPG9FVVOR NWCwU414UUN3ME2wMlA{QSEQvF2= NF\Yc44zOTR2OEW5NS=>
CHLA-140 NVL4T5E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\WTVExKM7:TR?= MW[5OkBp MUPEUXNQ MoG1TWM2OD1yLkCyOkDPxE1? M1;2ZVIyPDR6NUmx
LA-N-6 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljLNVAh|ryP Mn34PVYhcA>? NXjmSoQ5TE2VTx?= NWW4NJhFUUN3ME2wMlA2PCEQvF2= M4HkcVIyPDR6NUmx
NB-1643 NGjxOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuxNEDPxE1? NGi2[mY6PiCq NYDYN4RXTE2VTx?= NHTDenBKSzVyPUCuNFM4KM7:TR?= MnjpNlE1PDh3OUG=
NB-EBc1 M3TPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYno[oVOOTBizszN NGnjdWo6PiCq NHjQNJNFVVOR MUPJR|UxRTBwMEWwJO69VQ>? M4K0UVIyPDR6NUmx
SK-N-BE-1 NV;xUYpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HzbFExKM7:TR?= M4nMV|k3KGh? M{DXVmROW09? M3jy[2lEPTB;MD6wNlgh|ryP NVX4bo9XOjF2NEi1PVE>
SK-N-BE-2 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHpeG03OTBizszN MYC5OkBp MoLiSG1UVw>? NY\sUXZ7UUN3ME2wMlA{PiEQvF2= MmLPNlE1PDh3OUG=
SMS-KAN MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGybGpnOTBizszN M{jJNFk3KGh? NX\5V2RKTE2VTx?= M{XteGlEPTB;MD6wN|Qh|ryP MUWyNVQ1QDV7MR?=
SMS-KANR NUezdnFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu5dXcyOCEQvF2= NHmzc3A6PiCq NV30R2UzTE2VTx?= MYPJR|UxRTBwMEK2JO69VQ>? MknmNlE1PDh3OUG=
SMS-KCN NXrTbpNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\r[XdHOTBizszN MVq5OkBp MYLEUXNQ MUPJR|UxRTBwMEG5JO69VQ>? MoDUNlE1PDh3OUG=
SMS-KCNR MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD5NVAh|ryP NVPFWphjQTZiaB?= MUDEUXNQ NH7JeXJKSzVyPUCuNFExKM7:TR?= MmPCNlE1PDh3OUG=
SMS-LHN NV;SNlRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVizTG5nOTBizszN MmnlPVYhcA>? M1HtOmROW09? NF7IboxKSzVyPUCuNFMzKM7:TR?= NIXNZVgzOTR2OEW5NS=>
SMS-MSN MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\B[5oyOCEQvF2= M1TsWFk3KGh? NV7xRnh5TE2VTx?= MYPJR|UxRTBwMEKyJO69VQ>? M1;vVVIyPDR6NUmx
SMS-SAN MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKxNEDPxE1? MUW5OkBp NWXuPWZZTE2VTx?= NUDJNINoUUN3ME2wMlAzOCEQvF2= NHLJfYMzOTR2OEW5NS=>
Granta-4 NFHBW25EgXSxdH;4bYMhSXO|YYm= Mn7yNVAh|ryP MY[3JIQ> MXzJR|UxRTBwMESwJO69VQ>? NIHrRVIzOTJ7MUi2Oy=>
DB NV6w[oM5S3m2b4TvfIlkKEG|c3H5 Mmm0NVAh|ryP NESyVHQ4KGR? M2XlVmlEPTB;MD6wOFIh|ryP NV2wNIhDOjF{OUG4Olc>
RL M2TzSWN6fG:2b4jpZ{BCe3OjeR?= MkTDNVAh|ryP MWm3JIQ> NVXlPYhiUUN3ME2wMlAyPSEQvF2= M2PRU|IyOjlzOE[3
K562 M4\Ucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfhNVAh|ryP NH[3ZYE6PiCq MkfFTWM2OD1yLkC4O{DPxE1? M{T1PFIyODlzNkOz
LAMA-84 M{jpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;tdottOTBizszN NU\DXGNrQTZiaB?= M33FOmlEPTB;MD6wOVch|ryP MlX5NlExQTF4M{O=
MM15 M4PtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe0VmU1KM7:TR?= NEHEXmg4OiCq MWDEUXNQ NUjK[Wx6UUN3ME2wMlE{KM7:TR?= NELieZQzODN6Mki0OC=>
OPM1 NUDvV5JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[0b3c1KM7:TR?= M1:2dFczKGh? NX;Obok5TE2VTx?= MkXVTWM2OD1yLkCzJO69VQ>? M3TXdFIxOzh{OES0
RPM1 NWXRVpU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV20JO69VQ>? M13wd|czKGh? Mn;ZSG1UVw>? NEHkR5FKSzVyPUGwMlMzKM7:TR?= NXHUW4ZiOjB|OEK4OFQ>
INA6 MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnZOEDPxE1? MXi3NkBp MULEUXNQ NYK2bpNFUUN3ME2wMlAxOiEQvF2= M330O|IxOzh{OES0
OPM2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWK0JO69VQ>? NHfHNIM4OiCq MV3EUXNQ NWXlW4s{UUN3ME20MlM4KM7:TR?= MYKyNFM5Ojh2NB?=
MM1R NFTrfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnnOEDPxE1? Mn\MO|IhcA>? NHWyWVFFVVOR MlPQTWM2OD1zLk[4JO69VQ>? NWizTIVKOjB|OEK4OFQ>
DOX40 NV\5OFF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7XOEDPxE1? MV23NkBp NF\RfoFFVVOR MVrJR|UxRTVwNEig{txO NUi1[HF7OjB|OEK4OFQ>
LR5 NWXiUYdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLROEDPxE1? NXfHZYJtPzJiaB?= NHzaXGVFVVOR M3K2TGlEPTB;Mj61N{DPxE1? MXmyNFM5Ojh2NB?=
U266 M2rlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXhTXRRPCEQvF2= MYK3NkBp NITRd4hFVVOR MX7JR|UxRTFwNEOg{txO MUeyNFM5Ojh2NB?=
RD MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKxNEDPxE1? MkDzPVYhcA>? M2nmcGlEPTB;MD6yNlgh|ryP NXnGe|FbOjBzMEizN|g>
Rh41 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD5NVAh|ryP Ml76PVYhcA>? NGO5UWlKSzVyPUCuNFkxKM7:TR?= MWeyNFExQDN|OB?=
Rh30 NH20UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzRNVAh|ryP NGjNV|k6PiCq M{DuSmlEPTB;MD6yN|Ah|ryP NF\ifY0zODFyOEOzPC=>
BT-12 NV73dYZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XudVExKM7:TR?= MYm5OkBp M{D0eWlEPTB;MD6wOlAh|ryP MojFNlAyODh|M{i=
CHLA-266 NW[xTYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTFZpMyOCEQvF2= M1fQbVk3KGh? MXnJR|UxRTBwMEeyJO69VQ>? MWmyNFExQDN|OB?=
TC-71 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSxNEDPxE1? M4TBSlk3KGh? NWftXVNGUUN3ME2wMlExOiEQvF2= MoHCNlAyODh|M{i=
SJ-GBM2 NYO4XIxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEexXmoyOCEQvF2= MlHJPVYhcA>? MojXTWM2OD1yLkC1NEDPxE1? M3frblIxOTB6M{O4
NALM-6 NILIXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\s[VExKM7:TR?= MYG5OkBp MnW3TWM2OD1yLkC2NkDPxE1? NGDhSpIzODFyOEOzPC=>
COG-LL-317 NXTNRoRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7YboMyOCEQvF2= NHjibGo6PiCq NXXtNWNCUUN3ME2wMlA1PyEQvF2= MVSyNFExQDN|OB?=
RS4-11 NIHwWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYixNEDPxE1? Mn\yPVYhcA>? MWrJR|UxRTBwMEG4JO69VQ>? NYDKV3hsOjBzMEizN|g>
MOLT-4 NFXIPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmxNEDPxE1? M36yVVk3KGh? M4D2VWlEPTB;MD6wNlYh|ryP NXKxXVJkOjBzMEizN|g>
CCRF-CEM MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNEDPxE1? NHPBRY06PiCq MnHLTWM2OD1yLkC5OEDPxE1? MmTMNlAyODh|M{i=
Kasumi-1 NWnVVpFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\vfI5WOTBizszN NFnxOpk6PiCq M1nnSmlEPTB;MD6xNFMh|ryP NEjHe4czODFyOEOzPC=>
Karpas-299 M1ryNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPmNm5ZOTBizszN Mn3PPVYhcA>? MYfJR|UxRTBwMEO4JO69VQ>? NH;NeZQzODFyOEOzPC=>
Ramos-RA1 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:xNEDPxE1? NHHFZpE6PiCq Ml7ITWM2OD1yLkGyO{DPxE1? M33lblIxOTB6M{O4

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
15% Captisol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID